Lugano–Switzerland, Thursday, May 9th and Friday, May 10th 2019
Organized in collaboration with the Working Group on Cardiovascular Pharmacotherapy (European Society of Cardiology), the Swiss Society of Cardiology (SSC), the Swiss Atherosclerosis Association, and the French Society of Cardiology
Programme and inscription:
https://www.iscp2019.com
Preliminary programme
Course Directors: Prof Augusto Gallino, Bellinzona CH, Prof Juan Carlos Kaski, London GB, Prof Alexandre Fredenrich, Bellinzona CH/Nice FR, Prof Heinz Drexel, Feldkirch AT
Thursday, May 9th 2019
08.10–08.15: Brief opening of the meeting
08.15–09.35: World epidemics – Joint Session with ESC Working Group on Cardiovascular Pharmacotherapy
09.35–10.35: A changing paradigm in management of dyslipidemia
10.35–11.05 Coffee break
11.05–12.20: Anti-inflammatory treatment in coronary artery disease with participation of P. Libby
12.05–12.30: Key lecture: Cardiovascular pharmacotherapy in the elderly
12.30–13.30: PCSK9 inhibitors: How to bridge from high clinical value to access for patients?
12.30–13.30 Lunch
13.30–14.20: Medical vs invasive treatment strategies in stable coronary artery disease: debate session
14.20–15.20: Emerging indications for new oral anticoagulation in stable coronary artery disease
15.20‒15.50: Coffee break
15.50–16.35: Antithrombotic treatment in acute coronary artery disease in the world of emerging stents
16.35–17.30: PCSK-9 inhibition: Insights from the ODYSSEY OUTCOMES Trial
17.30–18.00: Distinguished Eugene Braunwald Lecture given by Eugene Braunwald
18.00–18.30: Neufeld Lecture given by / and awarded to Salim Yusuf
Friday, May 10th 2019
08.15–09.30: Atrial fibrillation
09.30–10.10: Chronic heart failure: a paradigm shift
10.40–11.15: Key lecture: Acute heart failure
11.15–11.45: State of the art lecture: Pharmacotherapy of the future: From Molecules to genetic tools
11.45–12.45: New antidiabetic drugs improve cardiovascular morbidity and mortality in patients with coronary artery disease and diabetes
12.45–13.15: Key lecture: Cardiovascular effects of incretin-based therapies: lessons from the trials testing GLP1 RAs
13.15–14.00: The emerging role of PCSK9 inhibitors after ACS
13.15‒14.15: Lunch
14.15–15.15: Arterial hypertension
15.15–15.40: Aspirin in primary prevention: a paradigm change?
15.40–16.20: Ventricular and atrial remodeling ‒ the road to heart failure and stroke: future approaches (joint session with the French Society of Cardiology)
16.20–16.45: ISCP awards
16.45: End of the Meeting
